Mineralocorticoid receptor mediates heart failure in the 11ß-hydroxysteroid dehydrogenase type 2 transgenic mouse model

被引：0
作者：
Qin, WN
Bond, BR
Donoho, GP
Heyen, JR
Frierdich, GE
Bolten, CW
Funder, JW
McMahon, EG
机构：
[1] Pfizer Inc, Groton, CT 06340 USA
[2] Pfizer Inc, St Louis, MO USA
[3] Pfizer Inc, Kalamazoo, MI USA
[4] Pfizer Inc, La Jolla, CA USA
[5] Prince Henrys Inst Med Res, Melbourne, Vic, Australia
来源：
CIRCULATION | 2004年 / 110卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2946
引用
收藏
页码：634 / 634
页数：1
相关论文
共 50 条
[21]   Expression of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II in renal cell neoplasms:: A tissue microarray study [J].
Yakirevich, E. ;
Morris, D. J. ;
Tavares, R. ;
Leehpammer, M. ;
Wang, L. J. ;
Sabo, E. ;
DeLellis, R. A. ;
Resnick, M. B. .
LABORATORY INVESTIGATION, 2007, 87 :184A-184A
[22]   Expression of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II in cutaneous adnexal neoplasms:: A tissue microarray study [J].
Laga, A. C. ;
Yakirevich, E. ;
Morris, D. J. ;
Tavares, R. ;
Noble, L. ;
DeLellis, R. A. ;
Resnick, M. B. .
MODERN PATHOLOGY, 2008, 21 :96A-96A
[23]   Expression of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II in cutaneous adnexal neoplasms:: A tissue microarray study [J].
Laga, A. C. ;
Yakirevich, E. ;
Morris, D. J. ;
Tavares, R. ;
Noble, L. ;
DeLellis, R. A. ;
Resnick, M. B. .
LABORATORY INVESTIGATION, 2008, 88 :96A-96A
[24]   Expression of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II in renal cell neoplasms:: A tissue microarray study [J].
Yakirevich, E. ;
Morris, D. J. ;
Tavares, R. ;
Lechpammer, M. ;
Wang, L. J. ;
Sabo, E. ;
DeLellis, R. A. ;
Resnick, M. B. .
MODERN PATHOLOGY, 2007, 20 :184A-184A
[25]   LOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR [J].
EDWARDS, CRW ;
BURT, D ;
MCINTYRE, MA ;
DEKLOET, ER ;
STEWART, PM ;
BRETT, L ;
SUTANTO, WS ;
MONDER, C .
LANCET, 1988, 2 (8618) :986-989
[26]   Two homozygous mutations in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess [J].
Carvajal, CA ;
Gonzalez, AA ;
Romero, DG ;
González, A ;
Mosso, LM ;
Lagos, ET ;
Hevia, MD ;
Rosati, MP ;
Perez-Acle, TO ;
Gomez-Sanchez, CE ;
Montero, JA ;
Fardella, CE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (06) :2501-2507
[27]   A mutation in the cofactor-binding domain of 11β-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertensions [J].
Odermatt, A ;
Dick, B ;
Arnold, P ;
Zaehner, T ;
Plueschke, V ;
Deregibus, MN ;
Repetto, H ;
Frey, BM ;
Frey, FJ ;
Ferrari, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1247-1252
[28]   Impaired protein stability of 11β-hydroxysteroid dehydrogenase type 2:: A novel mechanism of apparent mineralocorticoid excess [J].
Atanasov, Atanas G. ;
Ignatova, Irena D. ;
Nashev, Lyubomir G. ;
Dick, Bernhard ;
Ferrari, Paolo ;
Frey, Felix J. ;
Odermatt, Alex .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (04) :1262-1270
[29]   Two elderly patients with mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) impairment [J].
Inada, Mitsuo ;
Iwasaki, Keiko ;
Imai, Chihiro ;
Hashimoto, Satoshi .
INTERNAL MEDICINE, 2008, 47 (07) :631-636
[30]   Reduced brain 11β-hydroxysteroid dehydrogenase type 2 activity contributes to sympathetic excitation in heart failure rats [J].
Zhang, ZH ;
Yu, Y ;
Wei, SG ;
Kang, YM ;
Felder, RB .
CIRCULATION, 2005, 112 (17) :U133-U133
12345